<?xml-stylesheet type="text/xsl" href="ViewNLM-v2.3.xsl"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Korean J Intern Med</journal-id><journal-id journal-id-type="publisher-id">KJIM</journal-id><journal-title-group><journal-title>The Korean Journal of Internal Medicine</journal-title></journal-title-group><issn pub-type="ppub">1226-3303</issn><issn pub-type="epub">2005-6648</issn><publisher><publisher-name>The Korean Association of Internal Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19721860</article-id><article-id pub-id-type="pmc">2732783</article-id><article-id pub-id-type="doi">10.3904/kjim.2009.24.3.233</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Hye Eun</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Joon Chang</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Hyoung</surname><given-names>Bok Jin</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Hwang</surname><given-names>Hyeon Seok</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>So Young</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Jeon</surname><given-names>Youn Joo</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Bum Soon</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Yong Soo</given-names></name><xref ref-type="aff" rid="A1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Chul Woo</given-names></name><xref ref-type="aff" rid="A1"/></contrib></contrib-group><aff id="A1">Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.</aff><author-notes><corresp>Correspondence to Chul Woo Yang, M.D. Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, 505 Banpo-dong, Seocho-gu, Seoul 137-040, Korea. Tel: 82-2-2258-7569, Fax: 82-2-536-0323, <email>yangch@catholic.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>26</day><month>8</month><year>2009</year></pub-date><volume>24</volume><issue>3</issue><fpage>233</fpage><lpage>237</lpage><history><date date-type="received"><day>30</day><month>8</month><year>2008</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 The Korean Association of Internal Medicine</copyright-statement><copyright-year>2009</copyright-year></permissions><abstract><sec><title>Background/Aims</title><p>The efficacy and safety of a combination of ezetimibe and low-dose statin as primary treatment for dyslipidemia in renal transplant patients were evaluated prospectively.</p></sec><sec><title>Methods</title><p>The study enrolled 77 renal transplant recipients with dyslipidemia. They were given ezetimibe (10 mg) and simvastatin (10 mg) for 6 months as the initial treatment for dyslipidemia. Efficacy and safety were evaluated using lipid profiles, trough calcineurin inhibitor levels, allograft function, and adverse effects. The effects on proteinuria and high sensitivity C-reactive protein (hsCRP) levels were also evaluated.</p></sec><sec><title>Results</title><p>Ezetimibe and low-dose simvastatin significantly decreased the levels of total cholesterol (34.6%), triglyceride (16.0%), and low-density lipoprotein cholesterol (LDL-C) (47.6%), and 82.5% of the patients reached the target LDL-C level of &#x0003c;100 mg/dL. No significant change in the trough calcineurin inhibitor levels or allograft function occurred, and no serious adverse effects were observed. Fourteen patients (18.2%) discontinued treatment; eight patients (11.7%) developed muscle pain or weakness without an increase in creatinine kinase levels, and two patients (2.6%) developed elevated liver transaminase levels. The proteinuria and hsCRP levels did not change significantly.</p></sec><sec><title>Conclusions</title><p>Ezetimibe and low-dose statin treatment is safe and effective as a primary treatment for dyslipidemia in renal transplant patients.</p></sec></abstract><kwd-group><kwd>Ezetimibe</kwd><kwd>Statin</kwd><kwd>Dyslipidemias</kwd><kwd>Kidney transplantation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Dyslipidemia, a major complication in renal transplant patients, increases the risk of cardiovascular disease (CVD) [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>], which is a major cause of morbidity and mortality in the renal transplant population [<xref ref-type="bibr" rid="B3">3</xref>]. The clinical practice guidelines of the National Kidney Foundation Work Group recommend a target low-density lipoprotein cholesterol (LDL-C) level of less than 100 mg/dL [<xref ref-type="bibr" rid="B4">4</xref>], and the use of a statin as the first-line treatment. Nevertheless, in clinical practice, many patients fail to reach the target LDL-C level. The reasons for this may be multifactorial, but include a tendency to reduce the statin dose because of concerns about the adverse effects related to higher doses and drug interactions between the statin and calcineurin inhibitors (CNIs) [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Ezetimibe lowers cholesterol levels by inhibiting the intestinal absorption of cholesterol [<xref ref-type="bibr" rid="B6">6</xref>] so ezetimibe is especially useful for patients who are statin-intolerant or resistant to high-dose statin monotherapy [<xref ref-type="bibr" rid="B7">7</xref>]. The incremental lipid-lowering effect of ezetimibe has been observed in both non-transplant [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B18">18</xref>] and renal transplant populations [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. However, no report has examined the use of ezetimibe combined with a low-dose statin as the initial treatment in renal transplant patients.</p><p>This study prospectively evaluated the efficacy and safety of ezetimibe and low-dose simvastatin therapy as primary treatment for dyslipidemia in renal transplant recipients. Our results revealed that primary treatment of renal transplant recipients with ezetimibe and low-dose simvastatin lowers lipid levels dramatically without significant adverse reactions.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study population</title><p>A prospective study examined renal transplant recipients receiving a single combination tablet of ezetimibe (10 mg) and simvastatin (10 mg) daily. The inclusion criteria were the passage of at least 4 months after renal transplantation, fasting LDL-C levels over 100 mg/dL despite therapeutic lifestyle changes, and informed consent of the patient. Patients who had one or more of the following criteria were excluded: use of other lipid-lowering drugs (including statin monotherapy) within 4 weeks of the start of ezetimibe and simvastatin therapy, an episode of unstable angina or myocardial infarction within the past 6 months, preexisting malignancy with a life expectancy of less than 1 year, abnormal liver enzymes (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) &#x02265;2&#x000d7; the upper limit of normal, and pregnant or breast-feeding women.</p></sec><sec><title>Study protocol</title><p>After a 1-month screening period, eligible patients were enrolled in the study. The doses of simvastatin and ezetimibe were not changed during the study period. Study visits were scheduled before initiating treatment and after 2 weeks and 1, 3, and 6 months. Fasting lipid profiles (total cholesterol [TC], triglyceride [TG], LDL-C, and high-density lipoprotein cholesterol [HDL-C]), creatinine kinase (CK), and trough immunosuppressant levels (cyclosporin A [CsA], tacrolimus [Tac], and sirolimus [SRL]) were measured at all scheduled visits. The urine protein-to-creatinine ratio in a spot urine sample, liver transaminase (AST, ALT), and high sensitivity C-reactive protein (hsCRP) were measured before initiating treatment and after 1, 3, and 6 months. Adverse drug reactions, such as myalgia and skin rash, were monitored at all scheduled visits. Treatment compliance was assessed after 1, 3, and 6 months. The study protocol was approved by the institutional review board.</p></sec><sec><title>Data and statistical analysis</title><p>The following variables were analyzed before and after ezetimibe and low-dose simvastatin treatment: fasting lipid profiles (TC, TG, LDL-C, and HDL-C), estimated glomerular filtration rate (eGFR), urine protein-to-creatinine ratio in a spot urine sample, liver transaminase (AST, ALT), hsCRP, CK, trough immunosuppressant levels (CsA, Tac, and SRL), and adverse drug reactions. LDL-C was calculated using Friedewald's equation (LDL-C=TC-[TG/5]-[HDL-C] and eGFR was calculated using the abbreviated Modification of Diet and Renal Disease (MDRD) equation [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>Continuous data are presented as the median and range or mean&#x000b1;SD and were compared using the paired <italic>t</italic>-test. In a subgroup analysis of patients with proteinuria (&#x02265;500 mg/g) or high hsCRP levels (&#x02265;0.5 mg/dL), data including proteinuria and hsCRP levels were compared using the Wilcoxon signed-rank test.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Patient characteristics</title><p>Seventy-seven patients were enrolled in this study. The patient characteristics are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. Three patients were on CNI-free regimens (SRL and prednisolone) and two patients were on corticosteroid-free regimens (CsA and mycophenolate mofetil). Fifty-six patients were on a triple immunosuppressive regimen and 21 patients were on a dual immunosuppressive regimen. Sixty-three patients (81.8%) continued on ezetimibe and low-dose simvastatin therapy for the full 6 months.</p></sec><sec><title>Effects of ezetimibe and low-dose simvastatin on lipid panels</title><p>The overall effects of treatment on the fasting lipid profiles are shown in <xref ref-type="table" rid="T2">Table 2</xref>. The TC, TG, and LDL-C levels were reduced significantly after treatment with mean percentage changes of 34.6&#x000b1;9.5, 16.0&#x000b1;27.4, and 47.6&#x000b1;13.7%, respectively. After 6 months of treatment, 52 patients (82.5%) reached the target of LDL-C &#x0003c;100 mg/dL.</p><p>An analysis of subgroups divided according to the type of CNI showed that the lipid-lowering effect was significant in both the CsA and Tac groups (<xref ref-type="table" rid="T3">Table 3</xref>). In CsA-treated patients, the levels of TC, TG, and LDL-C were reduced significantly with mean percentage changes of 33.9&#x000b1;6.5, 12.0&#x000b1;29.5, and 47.2&#x000b1;9.9%, respectively. In Tac-treated patients, the TC, TG, and LDL-C levels were significantly reduced with mean percentage changes of 35.8&#x000b1;12.0, 21.4&#x000b1;24.5, and 48.8&#x000b1;16.7%, respectively. Stable trough CsA and Tac levels were maintained. One patient was on SRL and had a trough level of 8.9 ng/mL before treatment and 9.5 ng/mL after treatment.</p></sec><sec><title>Effect of ezetimibe and low-dose simvastatin therapy on allograft function, proteinuria, and hsCRP levels</title><p>As shown in <xref ref-type="table" rid="T2">Table 2</xref>, no significant change occurred in the eGFR, urine protein-to-creatinine ratio, or hsCRP concentration after treatment. In a subgroup analysis of patients with proteinuria of at least 500 mg/g (n=16), the median urine protein-to-creatinine ratio was reduced from 1558.5 (range 500.4-5985.5) to 869.5 (range 93.2-6857.1) mg/g, but the difference was not significant (<italic>p</italic>=0.14). In a subgroup analysis of patients with hsCRP levels &#x02265;0.5 mg/dL (n=6), the median hsCRP concentration was reduced from 0.7 (range 0.5-1.0) to 0.3 (range 0.02-2.2) mg/dL, but statistical significance was not achieved (<italic>p</italic>= 0.6).</p></sec><sec><title>Adverse drug reactions</title><p>Fourteen patients (18.2%) discontinued the ezetimibe and low-dose simvastatin treatment. The most common reason was muscle pain or weakness (n=8, 11.7%) without a significant increase in CK levels. Two patients (2.6%) had greater than twofold increases in the upper limit levels of AST and ALT. Other reasons were skin rash, dizziness, pregnancy, and concomitant administration of itraconazole.</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Our results clearly demonstrate the lipid-lowering efficacy of a combination of ezetimibe and low-dose statin in renal transplant recipients with dyslipidemia. Four reports on the lipid-lowering efficacy of ezetimibe in renal transplant patients have been published [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B22">22</xref>], but these studies focused mainly on patients who were statin-intolerant or resistant to high-dose statin monotherapy. Compared to previous reports, our study provides evidence of the potential advantage of the combination of ezetimibe and low-dose statin as the initial treatment for dyslipidemia in this population.</p><p>The most important finding of this study is that treatment with a combination of ezetimibe and low-dose statin effectively lowered the LDL-C level in renal transplant recipients. With ezetimibe (10 mg) and simvastatin (10 mg), the LDL-C level was reduced 47.6% on average and 82.5% of the patients reached the LDL-C goal of &#x0003c;100 mg/dL (<xref ref-type="table" rid="T2">Table 2</xref>). Our results (47.6% reduction in the LDL-C level) are better than those of a study on statin monotherapy (fluvastatin, 40 mg) in a large number of renal transplant patients (32% reduction in the LDL-C level) [<xref ref-type="bibr" rid="B24">24</xref>]. Furthermore, we obtained better results than studies reporting an average 31% reduction (range 22-41%) in the LDL-C level using ezetimibe with or without high-dose statin treatment [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. The reason for the enhanced lipid-lowering effect seen in our study may be explained partially by the higher pretreatment LDL-C levels [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B22">22</xref>]. Nevertheless, it suggests that initial treatment with ezetimibe and low-dose statin has a more potent lipid-lowering effect than other regimens, such as statin monotherapy or the secondary addition of ezetimibe to a statin. This presumption is supported by the excellent results (45-54%) in non-transplant patients initially treated with ezetimibe and a statin [<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B18">18</xref>].</p><p>In addition to its excellent effect on dyslipidemia, renal transplant patients receiving a CNI would benefit from ezetimibe and low-dose statin therapy. The effective dose of ezetimibe is higher in patients receiving CsA than in patients not receiving CsA [<xref ref-type="bibr" rid="B25">25</xref>-<xref ref-type="bibr" rid="B27">27</xref>]. The mechanism of the interaction between ezetimibe and CsA is not fully understood, but CsA is thought to alter the glucuronidation of ezetimibe in gastrointestinal tissue, which alters the pharmacokinetics of ezetimibe and its metabolites [<xref ref-type="bibr" rid="B27">27</xref>]. Therefore, patients on CsA may have a higher lipid-lowering effect with lower doses of ezetimibe than those not receiving CsA.</p><p>Another advantage of the combination treatment with ezetimibe and low-dose statin is safety. In this study, the incidence of adverse reactions associated with statins was quite low. Only 2.6% of the patients developed elevated transaminase levels, which is a rate similar to that in the non-transplant population [<xref ref-type="bibr" rid="B28">28</xref>]. Muscle pain or weakness occurred in 11.7% of the patients, but it was nonspecific and was not associated with increased CK levels. The blood trough CNI levels and allograft function measured using the estimated GFR were stable during the 6-month treatment. This suggests that combination treatment with ezetimibe and low-dose statin has fewer adverse effects and induces less allograft dysfunction than high-dose statin therapy.</p><p>Our study has some limitations. First, it lacks randomization to compare ezetimibe plus low-dose statin with high-dose statin monotherapy. Second, the observation period was short and the study population was relatively small, which meant that we did not observe a beneficial effect of statin on reducing proteinuria or hsCRP levels.</p><p>In conclusion, the combination of ezetimibe and low-dose statin is an effective primary lipid-lowering therapy in renal transplant patients. This treatment may help more transplant patients to achieve the optimal LDL-C target compared to statin monotherapy.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Massy</surname><given-names>ZA</given-names></name><name><surname>Kasiske</surname><given-names>BL</given-names></name></person-group><article-title>Post-transplant hyperlipidemia: mechanisms and management</article-title><source>J Am Soc Nephrol</source><year>1996</year><volume>7</volume><fpage>971</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">8829110</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardine</surname><given-names>AG</given-names></name><name><surname>Fellstr&#x000f6;m</surname><given-names>B</given-names></name><name><surname>Logan</surname><given-names>JO</given-names></name><etal/></person-group><article-title>Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study</article-title><source>Am J Kidney Dis</source><year>2005</year><volume>46</volume><fpage>529</fpage><lpage>536</lpage><pub-id pub-id-type="pmid">16129216</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasiske</surname><given-names>BL</given-names></name><name><surname>Guijarro</surname><given-names>C</given-names></name><name><surname>Massy</surname><given-names>ZA</given-names></name><name><surname>Wiederkehr</surname><given-names>MR</given-names></name><name><surname>Ma</surname><given-names>JZ</given-names></name></person-group><article-title>Cardiovascular disease after renal transplantation</article-title><source>J Am Soc Nephrol</source><year>1996</year><volume>7</volume><fpage>158</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">8808124</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasiske</surname><given-names>B</given-names></name><name><surname>Cosio</surname><given-names>FG</given-names></name><name><surname>Beto</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative</article-title><source>Am J Transplant</source><year>2004</year><volume>4</volume><issue>Suppl 7</issue><fpage>13</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15027968</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhlaghi</surname><given-names>F</given-names></name><name><surname>McLachlan</surname><given-names>AJ</given-names></name><name><surname>Keogh</surname><given-names>AM</given-names></name><name><surname>Brown</surname><given-names>KF</given-names></name></person-group><article-title>Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients</article-title><source>Br J Clin Pharmacol</source><year>1997</year><volume>44</volume><fpage>537</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">9431828</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhop</surname><given-names>T</given-names></name><name><surname>Lutjohann</surname><given-names>D</given-names></name><name><surname>Kodal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Inhibition of intestinal cholesterol absorption by ezetimibe in humans</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>1943</fpage><lpage>1948</lpage><pub-id pub-id-type="pmid">12370217</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>EA</given-names></name></person-group><article-title>Managing dyslipidemia in the high-risk patient</article-title><source>Am J Cardiol</source><year>2002</year><volume>89</volume><issue>5A</issue><fpage>50C</fpage><lpage>57C</lpage><pub-id pub-id-type="pmid">11779522</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MH</given-names></name><name><surname>McGarry</surname><given-names>T</given-names></name><name><surname>Bettis</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>40</volume><fpage>2125</fpage><lpage>2134</lpage><pub-id pub-id-type="pmid">12505224</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melani</surname><given-names>L</given-names></name><name><surname>Mills</surname><given-names>R</given-names></name><name><surname>Hassman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial</article-title><source>Eur Heart J</source><year>2003</year><volume>24</volume><fpage>717</fpage><lpage>728</lpage><pub-id pub-id-type="pmid">12713766</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballantyne</surname><given-names>CM</given-names></name><name><surname>Houri</surname><given-names>J</given-names></name><name><surname>Notarbartolo</surname><given-names>A</given-names></name><name><surname>LeBeaut</surname><given-names>AP</given-names></name><name><surname>Sager</surname><given-names>P</given-names></name><name><surname>Veltri</surname><given-names>EP</given-names></name></person-group><article-title>Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>2409</fpage><lpage>2415</lpage><pub-id pub-id-type="pmid">12719279</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ose</surname><given-names>L</given-names></name><name><surname>Johnson-Levonas</surname><given-names>A</given-names></name><name><surname>Reyes</surname><given-names>R</given-names></name><etal/></person-group><article-title>A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet</article-title><source>Int J Clin Pract</source><year>2007</year><volume>61</volume><fpage>1469</fpage><lpage>1480</lpage><pub-id pub-id-type="pmid">17655686</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearson</surname><given-names>T</given-names></name><name><surname>Ballantyne</surname><given-names>C</given-names></name><name><surname>Sisk</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>A</given-names></name><name><surname>Veltri</surname><given-names>E</given-names></name><name><surname>Maccubbin</surname><given-names>D</given-names></name></person-group><article-title>Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels</article-title><source>Am J Cardiol</source><year>2007</year><volume>99</volume><fpage>1706</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">17560879</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landray</surname><given-names>M</given-names></name><name><surname>Baigent</surname><given-names>C</given-names></name><name><surname>Leaper</surname><given-names>C</given-names></name><etal/></person-group><article-title>The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD</article-title><source>Am J Kidney Dis</source><year>2006</year><volume>47</volume><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="pmid">16490616</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roeters van Lennep</surname><given-names>HW</given-names></name><name><surname>Liem</surname><given-names>AH</given-names></name><name><surname>Dunselman</surname><given-names>PH</given-names></name><name><surname>Dallinga-Thie</surname><given-names>GM</given-names></name><name><surname>Zwinderman</surname><given-names>AH</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name></person-group><article-title>The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study</article-title><source>Curr Med Res Opin</source><year>2008</year><volume>24</volume><fpage>685</fpage><lpage>694</lpage><pub-id pub-id-type="pmid">18226326</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagne</surname><given-names>C</given-names></name><name><surname>Bays</surname><given-names>H</given-names></name><name><surname>Weiss</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia</article-title><source>Am J Cardiol</source><year>2002</year><volume>90</volume><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">12423708</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sager</surname><given-names>PT</given-names></name><name><surname>Melani</surname><given-names>L</given-names></name><name><surname>Lipka</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein</article-title><source>Am J Cardiol</source><year>2003</year><volume>92</volume><fpage>1414</fpage><lpage>1418</lpage><pub-id pub-id-type="pmid">14675576</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastelein</surname><given-names>JJ</given-names></name><name><surname>Akdim</surname><given-names>F</given-names></name><name><surname>Stroes</surname><given-names>ES</given-names></name><etal/></person-group><article-title>Simvastatin with or without ezetimibe in familial hypercholesterolemia</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>1431</fpage><lpage>1443</lpage><pub-id pub-id-type="pmid">18376000</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bae</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name><name><surname>Jeon</surname><given-names>ES</given-names></name></person-group><article-title>The safety and efficacy of ezetimibe and simvastatin combination therapy in Korean patients with primary hypercholesterolemia</article-title><source>Korean J Med</source><year>2005</year><volume>68</volume><fpage>487</fpage><lpage>497</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puthenparumpil</surname><given-names>JJ</given-names></name><name><surname>Keough-Ryan</surname><given-names>T</given-names></name><name><surname>Kiberd</surname><given-names>M</given-names></name><name><surname>Lawen</surname><given-names>J</given-names></name><name><surname>Kiberd</surname><given-names>BA</given-names></name></person-group><article-title>Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population</article-title><source>Transplant Proc</source><year>2005</year><volume>37</volume><fpage>1033</fpage><lpage>1035</lpage><pub-id pub-id-type="pmid">15848614</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langone</surname><given-names>AJ</given-names></name><name><surname>Chuang</surname><given-names>P</given-names></name></person-group><article-title>Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors</article-title><source>Transplantation</source><year>2006</year><volume>81</volume><fpage>804</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">16534487</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohnle</surname><given-names>M</given-names></name><name><surname>Pietruck</surname><given-names>F</given-names></name><name><surname>Kribben</surname><given-names>A</given-names></name><name><surname>Philipp</surname><given-names>T</given-names></name><name><surname>Heemann</surname><given-names>U</given-names></name><name><surname>Witzke</surname><given-names>O</given-names></name></person-group><article-title>Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation</article-title><source>Am J Transplant</source><year>2006</year><volume>6</volume><fpage>205</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">16433776</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>L</given-names></name><name><surname>Corbett</surname><given-names>J</given-names></name><name><surname>Nelson</surname><given-names>E</given-names></name><name><surname>Shihab</surname><given-names>F</given-names></name></person-group><article-title>A retrospective analysis of ezetimibe treatment in renal transplant recipients</article-title><source>Am J Transplant</source><year>2006</year><volume>6</volume><fpage>770</fpage><lpage>774</lpage><pub-id pub-id-type="pmid">16539634</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000f6;ge</surname><given-names>U</given-names></name><name><surname>Gerhardt</surname><given-names>T</given-names></name><name><surname>Palmedo</surname><given-names>H</given-names></name><name><surname>Klehr</surname><given-names>HU</given-names></name><name><surname>Sauerbruch</surname><given-names>T</given-names></name><name><surname>Woitas</surname><given-names>RP</given-names></name></person-group><article-title>MDRD equations for estimation of GFR in renal transplant recipients</article-title><source>Am J Transplant</source><year>2005</year><volume>5</volume><fpage>1306</fpage><lpage>1311</lpage><pub-id pub-id-type="pmid">15888034</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holdaas</surname><given-names>H</given-names></name><name><surname>Fellstr&#x000f6;m</surname><given-names>B</given-names></name><name><surname>Jardine</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Effect of fluvastation on cardiac outcomes in renal transplant recipients: a multi center, randomized, placebo-controlled trial</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>2024</fpage><lpage>2031</lpage><pub-id pub-id-type="pmid">12814712</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koshman</surname><given-names>SL</given-names></name><name><surname>Lalonde</surname><given-names>LD</given-names></name><name><surname>Burton</surname><given-names>I</given-names></name><name><surname>Tymchak</surname><given-names>WJ</given-names></name><name><surname>Pearson</surname><given-names>GJ</given-names></name></person-group><article-title>Supratherapeutic response to ezetimibe administered with cyclosporine</article-title><source>Ann Pharmacother</source><year>2005</year><volume>39</volume><fpage>1561</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">16030077</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosoglou</surname><given-names>T</given-names></name><name><surname>Statkevich</surname><given-names>P</given-names></name><name><surname>Johnson-Levonas</surname><given-names>AO</given-names></name><name><surname>Paolini</surname><given-names>JF</given-names></name><name><surname>Bergman</surname><given-names>AJ</given-names></name><name><surname>Alton</surname><given-names>KB</given-names></name></person-group><article-title>Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions</article-title><source>Clin Pharmacokinet</source><year>2005</year><volume>44</volume><fpage>467</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">15871634</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>AJ</given-names></name><name><surname>Burke</surname><given-names>J</given-names></name><name><surname>Larson</surname><given-names>P</given-names></name><etal/></person-group><article-title>Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients</article-title><source>J Clin Pharmacol</source><year>2006</year><volume>46</volume><fpage>328</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">16490809</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasternak</surname><given-names>RC</given-names></name><name><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></name><name><surname>Bairey-Merz</surname><given-names>CN</given-names></name><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name></person-group><article-title>Lenfant C ACC/AHA/NHLBI clinical advisory on the use and safety of statins</article-title><source>Stroke</source><year>2002</year><volume>33</volume><fpage>2337</fpage><lpage>2341</lpage><pub-id pub-id-type="pmid">12215610</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Patient characteristics (n=77)</p></caption><graphic xlink:href="kjim-24-233-i001"/><table-wrap-foot><fn><p>Values are the median (range) or number (percentage).</p><p>GFR, glomerular filtration rate; CsA, cyclosporine; Tac, tacrolimus; SRL, sirolimus.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Overall effect of ezetimibe and low-dose simvastatin therapy on lipid profiles, allograft function, proteinuria, and hsCRP (n=63)</p></caption><graphic xlink:href="kjim-24-233-i002"/><table-wrap-foot><fn><p>Values are the median (range) or mean&#x000b1;SD.</p><p>hsCRP, high sensitivity C-reactive protein; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Effect of ezetimibe and low-dose simvastatin therapy on lipid profiles according to CsA and Tac</p></caption><graphic xlink:href="kjim-24-233-i003"/><table-wrap-foot><fn><p>Values are the median (range).</p><p>CsA, cyclosporine; Tac, tacrolimus; TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.</p></fn></table-wrap-foot></table-wrap></floats-group></article>